ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:

) announced that the US Patent and Trademark Office (USPTO) has issued a key patent covering ImmunoCellular's product candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens that are commonly expressed on glioblastoma. The claims of US Patent No. 8,871,211, which issued October 28, 2014, include methods of treating neural cancer by administering a dendritic cell composition comprising peptide epitopes of the six tumor antigens of ICT-107. The claims specifically cover administration of the recited dendritic cell composition to a patient suffering from glioma, which is inclusive of glioblastoma multiforme. "This patent provides important protection for ICT-107, and adds to ImmunoCellular's intellectual property estate for our cancer vaccine portfolio," said Andrew Gengos, ImmunoCellular Chief Executive Officer. The ICT-107 patent was issued to Cedars Sinai Medical Center, and is exclusively licensed to ImmunoCellular Therapeutics.